MMS Holdings Inc. has been selected by Health Data Research UK as a partner to support the International COVID-19 Data Alliance (ICODA) initiative. MMS was selected from a pool of the world’s clinical research organizations to provide data engineering services to support a globally coordinated, health data-led research response to tackle the COVID-19 pandemic.
ICODA is an open and inclusive global collaboration of life science, philanthropic and research organizations that have come together to harness the power of health data to respond to the COVID-19 pandemic. Uniting data from a broad set of contributors will enable discoveries that will help treat and prevent COVID-19 and coordinate effective data responses to health challenges of the future.
During the pilot phase of the project, MMS will provide flexible service levels based on the capability of each contributor to transform their data to ICODA standards. The MMS biometrics and data science team will provide simple guidance to the full range of data services and data mapping as needed.
After the pilot completes, MMS data scientists will use learnings to develop tools to further enable contributors such as open-source code and training that academic researchers can use to transform their own data. Additionally, later phases of the engagement may include data mapping and incorporation of real-world health data.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.